Form 8-K Arcturus Therapeutics For: Nov 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
UPDATE: Arcturus Therapeutics (ARCT) PT Raised to $30 at Goldman Sachs (CORRECTION)
November 9, 2021 6:51 AM EST(Updated - November 9, 2021 6:52 AM EST)
Goldman Sachs analyst Madhu Kumar raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $30.00 (from $28.00) while maintaining a Sell rating.
... More